Despite heavy competition, GE Healthcare will forge ahead with its ongoing acquisition spree, division chairman and CEO John Dineen has said. Execs are continuing their search for more information technology and life sciences diagnostic deals to help enhance the company's edge.
We all know the life sciences industry produces plenty of hype about new diagnostic advances, cutting-edge treatments and lifesaving surgeries. Many are profoundly amazing and life-changing inventions that have saved countless lives. But the truth is that much of patient diagnosis and care remains guesswork, trial, error and hope. Read more >>
Forget organic growth. In 2013, some of the biggest moves into new or expanded markets in the med tech world came through serious M&A activity.
The top deals announced or closed in 2013 created supergiants in the diagnostics and renal device spaces for the first time. One transaction helped a major device player expand its orthopedic device offerings. Another $1.1 billion purchase helped a pharmaceutical giant become a major maker of a birth control device implant in one fell swoop. Another international med tech player, always on the lookout for new business lines, snatched up a buzz-worthy maker of an endoscopic pill camera in a deal announced at the end of 2013 that just closed in February, gaining new revenue possibilities through a smart acquisition.
POPULAR COMMENT THREADS
Sequenom scored against Illumina's Verinata Health in a ruling at the U.S. Patent and Trademark Office involving noninvasive prenatal genetic diagnostic tech. Wasting no time, executives plan to use that decision as a weapon in an ongoing legal battle between the two California companies.
MDxHealth will ally with a Texas-based provider network in a deal that will greatly expand the reach of its signature prostate cancer molecular diagnostic test to millions of additional patients.
KineMed, a California biomarker test developer with IPO plans, is joining a consortium that will create a standard mouse model focused on diagnosis and tracking of early-onset diabetes.
A rapid diagnostic blood test for asthma--one that works even in mild cases, before symptoms appear--showed some promise in new research. What's more, the handheld device developed for the diagnostic process would cost little to use, they said.
Cepheid booked much higher sales during its fiscal 2014 first quarter and successfully launched new HPV and norovirus molecular diagnostic tests outside of the U.S. But the California company faced a net loss as it dealt with higher overall costs and continued to work through restructuring.
Investors drove Abbott Laboratories' stock higher the week before Easter, heartened by diagnostics sales that keep climbing even as its medical devices arm faced continued challenges.
From Our Sister Sites
France's bioMérieux reported a rise in quarterly earnings of 3.3%, compared to the first three months of 2013, to $512.50 million.
The Alzheimer's research field has been marked by one failure after another in pursuit of effective treatments, but Cambridge, MA-based NeuroPhage Pharmaceuticals thinks it can tackle the devastating disease with a novel approach.